Glaxo flu vaccine sales pegged at $2.1B

As the swine flu gathers pace around the world, analysts forecast windfall orders for GlaxoSmithKline's H1N1 vaccine, which they expect to generate at least $2.1 billion in sales next year. Report

Suggested Articles

While Lilly's 2018 launch Emgality is approved to prevent migraines, Reyvow is intended to treat them as they occur.

ICER's new draft review of RA drugs takes a different approach, reflecting how physicians treat the disease and the time horizon that's considered.

Johnson & Johnson is facing multibillion-dollar liabilities in thousands of talc and opioid cases. But that's not such a bad thing, one analyst said.